Pacific Edge’s American dream

Pacific Edge’s American dream
The US Affordable Care Act can be tricky to navigate. (Image: Getty)
Paul McBeth
Pacific Edge has long wanted to crack the United States market, which it has seen for a long time as validating the hundreds of millions spent in developing its Cxbladder non-invasive cancer detection tool. More than 20 years since listing, after it was spun out of University of Otago research, the company has raised $297.23 million selling shares and convertible preference shares and as people exercised options to fund accumulated losses of $216.8m and counting. That’s not going to change any time soon after the company crashed...

More Markets

NZ sharemarket up 0.4% after a2 Milk surge
Markets Market Close

NZ sharemarket up 0.4% after a2 Milk surge

The S&P/NZX 50 Index closed at 12,266.25, gaining 57.2 points or 0.47%.

Graham Skellern 14 Mar 2025
Goldman Sachs downgrades Fletcher Building to sell
Markets

Goldman Sachs downgrades Fletcher Building to sell

Goldman Sach analysts have a 12-month target price of A$2.85 ($3.14).

Rebecca Howard 14 Mar 2025
Rayonier exits NZ with $1.2b forestry sale
Primary Sector

Rayonier exits NZ with $1.2b forestry sale

An investment firm bought the stake, which included 116,145 hectares of forestry.

John Anthony 14 Mar 2025
NZME board told 'compromise or be rolled'
Markets

NZME board told 'compromise or be rolled'

Minority shareholders are falling in behind billionaire Jim Grenon's board coup.